6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03462641 (ClinicalTrials.gov)	March 9, 2018	6/3/2018	Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm	Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil Arm	Parkinson Disease	Drug: Flumazenil;Drug: Placebo	University of Michigan	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	50 Years	99 Years	All	26	Phase 1/Phase 2	United States
2	NCT03440112 (ClinicalTrials.gov)	January 29, 2018	26/1/2018	Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm	Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson	Parkinson Disease	Drug: Clarithromycin (Not used as of 4/2020);Drug: Placebo (Not used as of 4/2020);Drug: Transdermal flumazenil (Added 4/2020);Drug: Placebo (Added 4/2020)	Nicolaas Bohnen, MD, PhD	National Institute of Neurological Disorders and Stroke (NINDS)	Recruiting	50 Years	N/A	All	30	Phase 1/Phase 2	United States
3	JPRN-UMIN000011111	2013/07/16	15/07/2013	Spinal blood flow and metabolism in neurological diseases	Spinal blood flow and metabolism in neurological diseases - Spinal blood flow and metabolism in neurological diseases	motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophy	PET scan study with 11C-flumazenil PET scan study with 18F- FDG PET scan study with 15O-H2O	Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences	NULL	Recruiting	20years-old	Not applicable	Male and Female	70	Not applicable	Japan